|
Mar 13
|
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
|
|
Mar 7
|
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
|
|
Mar 6
|
Solid Biosciences to Participate at Upcoming Investor Conferences
|
|
Feb 29
|
14 Stocks With Heavy Insider Buying In 2024
|
|
Jan 15
|
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
|
|
Dec 9
|
While institutions invested in Solid Biosciences Inc. (NASDAQ:SLDB) benefited from last week's 68% gain, private equity firms stood to gain the most
|
|
Dec 8
|
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
|
|
Dec 7
|
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
|
|
Nov 17
|
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics
|
|
Nov 16
|
Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod
|
|
Nov 16
|
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
|
|
Nov 14
|
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
|